These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2226475)

  • 1. Animal models as predictors of the safety and efficacy of antibiotics.
    Zak O; O'Reilly T
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):472-8. PubMed ID: 2226475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antibiotics--resistance is futile.
    Powledge TM
    PLoS Biol; 2004 Feb; 2(2):E53. PubMed ID: 14966545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal regulations vs. political will: why human zoonotic infections increase despite precautionary bans on animal antibiotics.
    Cox LA; Ricci PF
    Environ Int; 2008 May; 34(4):459-75. PubMed ID: 18201762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.
    Dalhoff A; Ullmann U
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):479-87. PubMed ID: 2226476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critique of animal models in antibiotic research.
    Barza M
    Scand J Infect Dis Suppl; 1978; (14):109-17. PubMed ID: 279963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.
    Zhao M; Lepak AJ; Andes DR
    Bioorg Med Chem; 2016 Dec; 24(24):6390-6400. PubMed ID: 27887963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
    de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
    Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ciprofloxacin in animal models of infection.
    Andriole VT
    Am J Med; 1987 Apr; 82(4A):67-70. PubMed ID: 3555064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
    Schuetz P; Müller B; Christ-Crain M; Stolz D; Tamm M; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Kristoffersen KB; Burkhardt O; Welte T; Schroeder S; Nobre V; Wei L; Bhatnagar N; Bucher HC; Briel M
    Evid Based Child Health; 2013 Jul; 8(4):1297-371. PubMed ID: 23877944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active controlled studies in antibiotic drug development.
    Dane A
    Pharm Stat; 2011; 10(5):454-60. PubMed ID: 21956949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in linking preclinical anti-microbial research strategies with clinical outcomes for device-associated infections.
    Moriarty TF; Grainger DW; Richards RG
    Eur Cell Mater; 2014 Sep; 28():112-28; discussion 128. PubMed ID: 25214018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical impact of appropriate use of antibiotic in hospital according to CARAT criteria].
    File TM
    Infez Med; 2008 Apr; 16 Suppl2():30-7. PubMed ID: 18843222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.
    van Meer PJ; Graham ML; Schuurman HJ
    Eur J Pharmacol; 2015 Jul; 759():3-13. PubMed ID: 25818943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitions of antibacterial interactions in animal infection models.
    Renneberg J
    J Antimicrob Chemother; 1993 May; 31 Suppl D():167-75. PubMed ID: 8335518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of antibacterial activities of antibiotics in vitro and in animal models of infection.
    Zak O; Tosch W; Sande MA
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():273-82. PubMed ID: 3980330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.
    Wong JP; DiTullio P; Parkinson S
    Future Microbiol; 2015; 10(11):1751-8. PubMed ID: 26597426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antibiotics: are we still in the pre-post-antibiotic era?
    Draenert R; Seybold U; Grützner E; Bogner JR
    Infection; 2015 Apr; 43(2):145-51. PubMed ID: 25701222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
    Johnson AP; Leibovici L
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
    [No Abstract]   [Full Text] [Related]  

  • 20. The future--can we learn from the past?
    Craig WA
    Diagn Microbiol Infect Dis; 1997; 27(1-2):49-53. PubMed ID: 9127106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.